Dose-Escalation Study of TPI 287 + Avastin Followed by Randomized Study of the Same Versus Avastin for Glioblastoma
Phase 1/2 Dose-Escalation Study of TPI 287 in Combination With Bevacizumab Followed by Randomized Study of the Maximum Tolerated Dose of TPI 287 in Combination With Bevacizumab Versus Bevacizumab Alone in Adults With Recurrent Glioblastoma
Sponsor: Cortice Biosciences, Inc.
Suspended
Business reasons
This PHASE1/PHASE2 trial investigates Glioblastoma Multiforme and is currently suspended. Cortice Biosciences, Inc. leads this study, which shows 11 recorded versions since 2013 — indicating substantial longitudinal coverage. The change history captured here reflects the iterative nature of clinical trial conduct.
Status Flow
Change History
11 versions recorded-
Sep 2025 — Present [monthly]
Suspended PHASE1/PHASE2
-
Sep 2024 — Sep 2025 [monthly]
Suspended PHASE1/PHASE2
-
Jul 2024 — Sep 2024 [monthly]
Suspended PHASE1/PHASE2
Phase: PHASE1_PHASE2 → PHASE1/PHASE2
-
Mar 2023 — Jul 2024 [monthly]
Suspended PHASE1_PHASE2
-
Sep 2022 — Mar 2023 [monthly]
Suspended PHASE1_PHASE2
▶ Show 6 earlier versions
-
Jan 2021 — Sep 2022 [monthly]
Suspended PHASE1_PHASE2
-
Dec 2020 — Jan 2021 [monthly]
Suspended PHASE1_PHASE2
-
Jun 2018 — Dec 2020 [monthly]
Suspended PHASE1_PHASE2
-
May 2018 — Jun 2018 [monthly]
Suspended PHASE1_PHASE2
Status: Recruiting → Suspended
-
Feb 2017 — May 2018 [monthly]
Recruiting PHASE1_PHASE2
-
Jan 2017 — Feb 2017 [monthly]
Recruiting PHASE1_PHASE2
First recorded
Aug 2013
Trial started
Per CT.gov start date — pre-dates our first snapshot
Eligibility Summary
No eligibility information available.
Contact Information
- Cortice Biosciences, Inc.
For direct contact, visit the study record on ClinicalTrials.gov .